Santhera Pharmaceuticals

About Santhera Pharmaceuticals

Santhera Pharmaceuticals is a specialty pharmaceutical company based in Switzerland, committed to the development and commercialization of innovative medicines for patients with rare diseases, particularly in the area of neuromuscular conditions.

Products & Services

AGAMREE® (vamorolone):A treatment focused on neuromuscular diseases, specifically for conditions with high unmet medical need.

Specialties

Rare Diseases Neuromuscular Conditions Medicine Research and Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Royalty Monetization T: - FT: Royalty Monetization	A: 13000000 MR: - FA: USD 13 million FAN: 13000000	D: 2025-11-05 FD: 2025-11-05	2 investors
2	RT: Growth Funding T: - FT: Growth Funding	A: 20000000 MR: - FA: CHF 20 million FAN: 20000000	D: 2025-09-23 FD: 2025-09-23	2 investors
3	RT: Convertible Bond T: - FT: Convertible Bond	A: 20132000 MR: - FA: CHF 20.132 million FAN: 20132000	D: 2025-09-23 FD: 2025-09-23	-
4	RT: Convertible Bond T: - FT: Convertible Bond	A: 7000000 MR: - FA: 7 million FAN: 7000000	D: 2025-08-15 FD: 2025-08-15	1 investors
5	RT: Debt T: - FT: Debt	A: 30000000 MR: - FA: approximately CHF 69 million FAN: 30000000	D: 2024-08-13 FD: 2024-08-13	2 investors
6	RT: Royalty and Debt Financing T: - FT: Royalty and Debt Financing	A: 38000000 MR: - FA: up to CHF 69 million FAN: 38000000	D: 2024-06-18 FD: 2024-06-18	2 investors
7	RT: Private Placement and Debt T: - FT: Private Placement and Debt	A: 24131400 MR: - FA: up to CHF 22.2 million FAN: 24131400	D: 2023-02-28 FD: 2023-02-28	1 investors
8	RT: Share Exchange T: - FT: Share Exchange	A: 5000000 MR: - FA: CHF 5 million FAN: 5000000	D: 2023-01-10 FD: 2023-01-10	1 investors

Royalty Monetization Latest

2025-11-05

$13.0M

2 investors (Pro only)

Growth Funding 2025-09-23

$20.0M

Convertible Bond 2025-09-23

$20.1M

View 7 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

T

Thomas Meier

Chairman of the Board

P

Philipp Gutzwiller

Board Member

B

Bradley C. Meyer

Board Member and Chairman of the Compensation Committee

M

Melanie Rolli

Group CEO

D

Dario Eklund

Chief Executive Officer (CEO)

C

Catherine Isted

Chief Financial Officer

View 10 more team members with Pro

Unlock Full Team Directory

Recent News